NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the United States Patent and Trademark Office has granted a new patent ...
Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take a drubbing. But at OSE Immunotherapeutics, which aims to prevent cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results